Skip to main content
Terug
RSLBF logo

RaySearch Laboratories AB (publ)

Datakwaliteit: 100%
Oversold
RSLBF
OTC Healthcare Medical - Healthcare Information Services
€ 23,00
€ 0,00 (0,00%)
Marktkapitalisatie: 822,17M
Dagbereik
€ 23,00 € 23,00
52-Weeksbereik
€ 20,60 € 37,36
Volume
7
50D / 200D Gem.
€ 25,46 / € 28,72
Vorige Slotkoers
€ 23,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 3,6 0,4
P/B 0,8 2,9
ROE % 24,5 3,8
Net Margin % 17,0 3,9
Rev Growth 5Y % 20,3 10,0
D/E 0,4 0,2

Belangrijkste Punten

Revenue grew 20,31% annually over 5 years — strong growth
ROE of 24,47% indicates high profitability
Net margin of 16,95% shows strong profitability
Debt/Equity of 0,40 — conservative balance sheet
Generating 158,90M in free cash flow
P/E of 3,61 — trading at a low valuation

Groei

Revenue Growth (5Y)
20,31%
Revenue (1Y)12,77%
Earnings (1Y)11,93%
FCF Growth (3Y)-19,73%

Kwaliteit

Return on Equity
24,47%
ROIC15,88%
Net Margin16,95%
Op. Margin21,74%

Veiligheid

Debt / Equity
0,40
Current Ratio1,70
Interest Coverage0,00

Waardering

P/E Ratio
3,61
P/B Ratio0,83
EV/EBITDA2,77
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12,77% Revenue Growth (3Y) 14,68%
Earnings Growth (1Y) 11,93% Earnings Growth (3Y) 67,11%
Revenue Growth (5Y) 20,31% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,34B Net Income (TTM) 227,80M
ROE 24,47% ROA 11,44%
Gross Margin 92,42% Operating Margin 21,74%
Net Margin 16,95% Free Cash Flow (TTM) 158,90M
ROIC 15,88% FCF Growth (3Y) -19,73%
Safety
Debt / Equity 0,40 Current Ratio 1,70
Interest Coverage 0,00 Dividend Yield 0,01%
Valuation
P/E Ratio 3,61 P/B Ratio 0,83
P/S Ratio 0,61 PEG Ratio 2,76
EV/EBITDA 2,77 Dividend Yield 0,01%
Market Cap 822,17M Enterprise Value 809,67M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,34B 1,19B 1,02B 843,65M 641,67M
Net Income 227,80M 203,51M 81,57M 23,78M -47,32M
EPS (Diluted) 6,65 5,94 2,38 0,69 -1,38
Gross Profit 1,24B 1,09B 915,58M 748,66M 591,28M
Operating Income 292,30M 260,49M 114,88M 42,74M -52,64M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,99B 2,09B 1,95B 1,88B 1,74B
Total Liabilities 1,01B 1,21B 1,22B 1,22B 1,12B
Shareholders' Equity 985,30M 876,71M 735,23M 657,16M 628,31M
Total Debt 394,80M 471,93M 529,36M 555,39M 561,40M
Cash & Equivalents 407,30M 462,74M 343,68M 160,27M 102,54M
Current Assets 970,70M 984,75M 802,45M 627,92M 516,37M
Current Liabilities 569,90M 703,82M 675,05M 614,10M 490,08M

Strategiescores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#673 of 820
26
Growth Price/Sales Ratio Focus (Ken Fisher)
#237 of 616
42
Custom Contrarian Investing (David Dreman)
#218 of 658
42
Value Defensive Investing (Benjamin Graham)
#144 of 708
49
Value Value Investing (Warren Buffett)
#132 of 195
36

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026